Current molecular biology and genetic mechanisms involved in MNPs are discussed.
Impact of JAK2V617F mutation as a diagnostic marker with a high frequency on MPN subgroup is described.
Impact of CALR mutations in MF and ET patients is addressed.
Favorable impact of type 1/type 1-like CALR mutations and unfavorable impact of ASXL1 mutations in PMF cases are discussed.
Genes involved in chromatin methylation and modifications are associated with MPNs.